Prevalence and Risk Factors for Neutralizing Antibodies to Human Papillomavirus Types 16 and 18 in HIV-Positive Men Who Have Sex With Men

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2013-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/QAI.0b013e3182a7acd2PMID 24231786PMCID PMC4287402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America.

  2012cited by this paper
• Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

  2012cited by this paper
• Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis.

  2012cited by this paper
• Human Papillomavirus (HPV) 6, 11, 16, and 18 Seroprevalence Is Associated with Sexual Practice and Age: Results from the Multinational HPV Infection in Men Study (HIM Study)

  2011cited by this paper
• Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men.

  2011cited by this paper
• A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

  2011cited by this paper
• HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.

  2011cited by this paper
• Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial

  2010cited by this paper
• Determinants of seropositivity among HPV-16/18 DNA positive young women

  2010cited by this paper
• Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.

  2010cited by this paper
• Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.

  2010cited by this paper
• Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

  2009influential reference
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  2009cited by this paper
• Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study.

  2009cited by this paper
• WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland.

  2009cited by this paper
• Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions

  2009cited by this paper
• Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

  2008cited by this paper
• Arrangement of L2 within the Papillomavirus Capsid

  2008cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

  2007cited by this paper
• Production of Papillomavirus‐Based Gene Transfer Vectors

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

  2007cited by this paper
• Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins

  2006cited by this paper
• Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer

  2006cited by this paper
• Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men

  2005cited by this paper
• Generation of HPV pseudovirions using transfection and their use in neutralization assays.

  2005cited by this paper
• Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

  2004cited by this paper
• A modified poisson regression approach to prospective studies with binary data.

  2004cited by this paper
• Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica

  2004cited by this paper
• Seroprevalence of human papillomavirus type 16 infection in the United States.

  2002cited by this paper
• Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.

  2001cited by this paper
• Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men.

  1998cited by this paper
• Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men.

  1998cited by this paper
• Evaluation of guidelines for initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV‐infected individuals

  1998cited by this paper
• Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.

  1998cited by this paper
• Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men.

  1997cited by this paper
• Vitamin C intake and susceptibility to pneumonia.

  1997cited by this paper
• Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.

  1996cited by this paper
• Polymerase chain reaction detection of human papillomavirus: quantitation may improve clinical utility

  1992cited by this paper
• Mapping of linear epitopes of human papillomavirus type 16: The E1, E2, E4, E5, E6 and E7 open reading frames

  1990cited by this paper
• Theory and Application of the Linear Model

  1976cited by this paper

• AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent Vaccine in Indian Women Living With HIV

  2021cites this paper
• Human papillomavirus antibody response following highly active antiretroviral therapy initiation among men who have sex with men

  2019influential citation
• Human Papillomavirus Vaccination and Infection in Young Sexual Minority Men: The P18 Cohort Study

  2019cites this paper
• HPV-Associated Anal Cancer in the HIV/AIDS Patient.

  2018cites this paper
• Human Papillomavirus Seroprevalence and Association with Anal HPV Infection and Squamous Intraepithelial Lesions in Australian Gay and Bisexual Men

  2018cites this paper
• Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men.

  2018cites this paper
• Human papillomavirus antibody response following HAART initiation among MSM

  2017influential citation
• Human papillomavirus epidemiology in men who have sex with men : implications for a vaccine programme at sexual health clinics in the UK

  2015cites this paper
• Limitations of human papillomavirus DNA testing in measuring previous exposure and vaccine protection

  2015cites this paper
• Use of human papillomavirus vaccine in HIV-infected men for the prevention of anal dysplasia and cancer.

  2014cites this paper